Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2024-10-24 AGM Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 17 pages 1.1MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT' and details the arrangements for the 2024 Annual General Meeting (AGM) of Syntara Limited, including the date, time, virtual meeting platforms, proxy voting instructions, and the agenda items such as adoption of the remuneration report, re-election of a director, approval of performance rights grants, and appointment of a new auditor. It includes procedural information for shareholders on voting restrictions, proxy submission, and participation in the virtual meeting. The document does not contain the actual financial statements or detailed financial performance data but serves as a formal notice and explanatory statement for the AGM. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), indicating it is not a brief announcement but a full notice and explanatory statement for the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2024-10-24 English
Change in substantial holding 3 pages 158.6KB
Major Shareholding Notification Classification · 95% confidence The document is very short (586 characters) and contains tabular data related to shareholdings, including percentages and disposal of shares. There is no indication of a full report, financial statements, or detailed narrative. The content resembles a notification of changes in significant share ownership levels, such as a major shareholding notification. There are no references to meetings, voting results, or management changes. Therefore, the document fits best into the category of Major Shareholding Notification (MRQ).
2024-10-20 English
Investor Presentation - Updated 15 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Syntara, a clinical stage drug developer, including investment highlights, financial information, board leadership, scientific research, clinical trial data, and strategic interest in assets. It contains forward-looking statements, detailed descriptions of clinical trials, drug development stages, and market opportunities. The content is structured as a comprehensive overview aimed at investors, covering financials, strategy, and scientific progress. There is no indication that this is an official annual or interim report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting result or legal proceeding. The presence of investment highlights, financial metrics, and strategic information strongly suggests this is an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-10-15 English
Application for quotation of securities - SNT 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used to apply for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options under an employee incentive scheme. The document includes specifics such as the number of securities, issue date, and class of securities. This type of filing is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities quotation.
2024-10-06 English
Date of 2024 AGM and closing date for director nomination 1
AGM Information Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange announcing the date of the 2024 Annual General Meeting (AGM) of Syntara Limited, specifying that it will be a virtual meeting and providing the closing date for director nominations. It does not contain the AGM materials or presentations themselves, nor does it include financial data or voting results. The document is short (985 characters) and serves as an announcement related to the AGM event. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements directly related to the AGM event.
2024-09-29 English
Application for quotation of securities - SNT 6 pages 18.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, and whether the securities are part of an employee incentive scheme. This type of filing is related to share issuance and capital changes rather than a financial report or management announcement. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not merely an announcement of a report but a formal application for quotation of securities.
2024-09-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.